NCT04222790View on ClinicalTrials.gov

A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions
Early Breast Cancer
Interventions
DRUG

monosialic gangliosides

The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).

OTHER

Placebo

The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)

Trial Locations (1)

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT04222790 - A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity | Biotech Hunter | Biotech Hunter